Metabolism and thermoregulation in the forest shrew Myosorex varius (Soricidae: Crocidurinae).

C. Brown,E. Hunter,R. Baxter

DOI: https://doi.org/10.1016/S0300-9629(97)00223-5

1997-12-01

Abstract:

What problem does this paper attempt to address?

Integrative Serum Metabolic Fingerprints Based Multi‐Modal Platforms for Lung Adenocarcinoma Early Detection and Pulmonary Nodule Classification

Lin Wang,Mengji Zhang,Xufeng Pan,Mingna Zhao,Lin Huang,Xiaomeng Hu,Xueqing Wang,Lihua Qiao,Qiaomei Guo,Wanxing Xu,Wenli Qian,Tingjia Xue,Xiaodan Ye,Ming Li,Haixiang Su,Yinglan Kuang,Xing Lu,Xin Ye,Kun Qian,Jiatao Lou

DOI: https://doi.org/10.1002/advs.202203786

IF: 15.1

2022-10-20

Advanced Science

Abstract:A multiplexed assay is developed on an optimized nanoparticle‐based laser desorption/ionization mass spectrometry platform for the sensitive detection of serum metabolic fingerprints (SMFs). Integrative SMFs based multi‐modal platforms are constructed for lung adenocarcinoma early detection by deep learning. The strategy is demonstrated to be practically feasible to aid the existing diagnostic approaches of lung cancer. Identification of novel non‐invasive biomarkers is critical for the early diagnosis of lung adenocarcinoma (LUAD), especially for the accurate classification of pulmonary nodule. Here, a multiplexed assay is developed on an optimized nanoparticle‐based laser desorption/ionization mass spectrometry platform for the sensitive and selective detection of serum metabolic fingerprints (SMFs). Integrative SMFs based multi‐modal platforms are constructed for the early detection of LUAD and the classification of pulmonary nodule. The dual modal model, metabolic fingerprints with protein tumor marker neural network (MP‐NN), integrating SMFs with protein tumor marker carcinoembryonic antigen (CEA) via deep learning, shows superior performance compared with the single modal model Met‐NN (p < 0.001). Based on MP‐NN, the tri modal model MPI‐RF integrating SMFs, tumor marker CEA, and image features via random forest demonstrates significantly higher performance than the clinical models (Mayo Clinic and Veterans Affairs) and the image artificial intelligence in pulmonary nodule classification (p < 0.001). The developed platforms would be promising tools for LUAD screening and pulmonary nodule management, paving the conceptual and practical foundation for the clinical application of omics tools.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
CancerScreen: A Novel Ultrasensitive Liquid Biopsy for Early-Stage Cancer Detection by Ctdna Duplex Sequencing and Tissue of Origin Identification with Supervised Machine Learning.

Elizabeth Ding,Zhilong Zhao,Hongsheng Xue,Jianxin Li,Ting Lei,Xuezhen Ma,Jianlin Wu,Qin Huang

DOI: https://doi.org/10.1200/jgo.2019.5.suppl.60

2019-01-01

Journal of Global Oncology

Abstract:60 Background: Circulating tumor DNA (ctDNA) in blood holds promise as a cancer-specific biomarker for early-stage cancer diagnosis. However, detection of ultra-low mutation allelic frequency (MAF) of ctDNA at early stages of cancer is infeasible by conventional next generation sequencing (NGS). Using duplex sequencing with unique molecular identifiers (UMIs) and custom-designed probes, we tested the hypothesis that ctDNA duplex sequencing with UMIs was able to detect ultra-low MAF of ctDNA in patients with early-stage cancers. Methods: A 128-gene panel that contains probes targeted to clinical relevant genome variations in cancers of the lung, stomach, and esophagus was designed and validated with reference DNA and controls using ctDNA duplex sequencing with UMIs. A data analysis pipeline was implemented withimproved algorithms for variant calling, blood tumor mutational burden (bTMB) calculation, and supervised machine learning for tissue-of-origin primary cancer identification. Results: We designed and validated a ctDNA duplex sequencing with UMIs assay that enables simultaneous detection of 128 clinical relevant geneswith SNPs, indels, amplifications, and fusions in a single blood test. Compared to conventional ctDNA NGS, our assay achieved high sensitivity (over 82%) and specificity (over 96%) with LOD at 0.1% MAF for stage I lung, gastric and esophageal cancers with the sequencing depth at 30,000x from a cohort of 136 clinical samples. Results also showed significant concordance of MAF and TMB between DNA from tumor tissues and plasma ctDNA. Our deep learning predictive model with novel algorithms and features for tumor tissue-of-origin classification achieved an overall 85% accuracy. Conclusions: In this study, a novel ultrasensitive assay was designed and validated for accurate detection of MAF at 0.1% from plasma ctDNA of multiple tumors, and accurate classification on tissue-of-origin for major primary cancers using supervised deep learning. The results of this liquid biopsy study from initial clinical testing showed its promise on clinical applications for early-stage cancer diagnosis.
Multiplexed Imaging with Coordination Nanoparticles for Cancer Diagnosis and Therapy

Jie Feng,Zhen Xu,Dan Luo,Xiaoqing Liu

DOI: https://doi.org/10.1021/acsabm.9b01038

2020-01-01

ACS Applied Bio Materials

Abstract:Multiplexed imaging offers great potential for precise and accurate diagnosis and therapy. Integrating multiplexed imaging with theranostics is promising to develop cancer therapeutics and diagnostics. However, the lack of versatile platforms with inherent different modalities and various probes hinders the potential of multiplexing imaging for cancer diagnosis and therapy. Here, we demonstrate that multiplexed imaging with advanced theranostic nanomaterials provides a potent method for cancer diagnostics and therapeutics both in vitro and in vivo. Unlike previous theranostic nanoplatforms, the prepared coordination nanomaterials have designable functionalities that are capable of imaging multiple intracellular biomarkers, multiple modality imaging, and photothermal ablation of tumor. Strikingly, this nanoplatform could specifically detect and image different tumor-related mRNAs simultaneously; allow infrared thermal, photoacoustic, and magnetic resonance imaging; and enable effective photothermal therapy to inhibit tumor growth in the MCF-7-derived mice xenograft tumor model. This study suggests that the nanoplatforms with designable functionalities may ultimately enable monitoring cancer processes, therapeutic mechanisms, and treatment outcomes. Exploring and exploiting multiplexed imaging with versatile theranostic nanoparticles may offer a powerful framework for precision medicine.
Noninvasive Cancer Detection by Extracting and Integrating Multi-Modal Data from Whole-Methylome Sequencing of Plasma Cell-Free DNA

Fenglong Bie,Zhijie Wang,Yulong Li,Yuanyuan Hong,Tiancheng Han,Fang Lv,Shunli Yang,Suxing Li,Xi Li,Peiyao Nie,Ruochuan Zang,Moyan Zhang,Peng Song,Fenling Feng,Wei Guo,Jianchun Duan,Guangyu Bai,Yuan Li,Qilin Huai,Bolun Zhou,Yu S. Huang,Weizhi Chen,Fengwei Tan,Shugeng Gao

DOI: https://doi.org/10.1101/2022.07.04.498641

2022-01-01

Abstract:Plasma cell-free DNA (cfDNA) methylation and fragmentation signatures have been shown to be valid biomarkers for blood-based cancer detection. However, conventional methylation sequencing assays are inapplicable for fragmentomic profiling due to bisulfite-induced DNA damage. Here using enzymatic conversion-based low-pass whole-methylome sequencing (WMS), we developed a novel approach to comprehensively interrogate the genome-wide plasma methylation, fragmentation, and copy number profiles for sensitive and noninvasive multi-cancer detection. With plasma WMS data from a clinical cohort comprising 497 healthy controls and 780 patients with both early- and advanced-stage cancers of the breast, colorectum, esophagus, stomach, liver, lung, or pancreas, genomic features including methylation, fragmentation size, copy number alteration, and fragment end motif were extracted individually and subsequently integrated to develop an ensemble cancer classifier, called THEMIS, using machine learning algorithms. THEMIS outperformed individual biomarkers for differentiating cancer patients of all seven types from healthy individuals and achieved a combined area under the curve value of 0.971 in the independent test cohort, translating to a sensitivity of 86% and early-stage (I and II) sensitivity of 77% at 99% specificity. In addition, we built a cancer signal origin classifier with true-positive cancer samples at 100% specificity based on methylation and fragmentation profiling of tissue-specific accessible regulatory elements, which localized cancer-like signal to a limited number of clinically informative sites with 66% accuracy. Overall, this proof-of-concept work demonstrates the feasibility of extracting and integrating multi-modal biomarkers from a single WMS run for noninvasive detection and localization of common cancers across stages.
Multidimensional Interactive Cascading Nanochips for Detection of Multiple Liver Diseases via Precise Metabolite Profiling

Zhiyu Li,Weili Peng,Juan Zhou,Shaoxuan Shui,Yicheng Liu,Tan Li,Xiaohui Zhan,Yuanyuan Chen,Fang Lan,Binwu Ying,Yao Wu

DOI: https://doi.org/10.1002/adma.202312799

Abstract:It is challenging to detect and differentiate multiple diseases with high complexity/similarity from the same organ. Metabolic analysis based on nanomatrix-assisted laser desorption/ionization mass spectrometry (NMALDI-MS) is a promising platform for disease diagnosis, while the enhanced property of its core nanomatrix materials has plenty of room for improvement. Herein, a multidimensional interactive cascade nanochip composed of iron oxide nanoparticles (FeNPs)/MXene/gold nanoparticles (AuNPs), IMG, is reported for serum metabolic profiling to achieve high-throughput detection of multiple liver diseases. MXene serves as a multi-binding site and an electron-hole source for ionization during NMALDI-MS analysis. Introduction of AuNPs with surface plasmon resonance (SPR) properties facilitates surface charge accumulation and rapid energy conversion. FeNPs are integrated into the MXene/Au nanocomposite to sharply reduce the thermal conductivity of the nanochip with negligible heat loss for strong thermally-driven desorption, and construct a multi-interaction proton transport pathway with MXene and AuNPs for strong ionization. Analysis of these enhanced serum fingerprint signals detected from the IMG nanochip through a neural network model results in differentiation of multiple liver diseases via a single pass and revelation of potential metabolic biomarkers. The promising method can rapidly and accurately screen various liver diseases, thus allowing timely treatment of liver diseases.
Non-invasive Lung Cancer Diagnosis and Prognosis Based on Multi-Analyte Liquid Biopsy.

Kezhong Chen,Jianlong Sun,Heng Zhao,Ruijingfang Jiang,Jianchao Zheng,Zhilong Li,Jiaxi Peng,Haifeng Shen,Kai Zhang,Jin Zhao,Shida Zhu,Yuying Wang,Fan Yang,Jun Wang

DOI: https://doi.org/10.1186/s12943-021-01323-9

IF: 37.3

2021-01-01

Molecular Cancer

Abstract:Chest LDCT provides an effective approach for lung cancer screening, yet has been found to generate a large number of false positives during practice due to excessive diagnosis of pulmonary lesions of indeterminate clinical significance. In this study, we performed comprehensive genetic and epigenetic profiling of cfDNA from lung cancer patients and individuals bearing benign lung lesions, using ultra-deep targeted sequencing and targeted bisulfite sequencing. We found that cfDNA mutation profile alone has relatively limited power in distinguishing malignant from benign plasma, while cfDNA methylation profiling showed a better performance for classification of the two groups and combination of genetic and epigenetic features of cfDNA along with serum protein marker further improved the classification accuracy. We also identified novel methylation-based prognostic markers and showed that an integrated model that combined cfDNA mutational status and methylation-based prognostic markers improved prediction for lung cancer survival. Our results highlight the potential of the multi-analyte assay for non-invasive lung cancer diagnosis and prognosis.
A Noninvasive Multianalytical Approach for Lung Cancer Diagnosis of Patients with Pulmonary Nodules

Quan‐Xing Liu,Dong Zhou,Tian‐Cheng Han,Xiao Lu,Bing Hou,Man‐Yuan Li,Gui‐Xue Yang,Qing‐Yuan Li,Zhi‐Hua Pei,Yuan‐Yuan Hong,Ya‐Xi Zhang,Wei‐Zhi Chen,Hong Zheng,Ji He,Ji‐Gang Dai

DOI: https://doi.org/10.1002/advs.202100104

IF: 15.1

2021-05-07

Advanced Science

Abstract:<p>Addressing the high false‐positive rate of conventional low‐dose computed tomography (LDCT) for lung cancer diagnosis, the efficacy of incorporating blood‐based noninvasive testing for assisting practicing clinician's decision making in diagnosis of pulmonary nodules (PNs) is investigated. In this prospective observative study, next generation sequencing‐ (NGS‐) based cell‐free DNA (cfDNA) mutation profiling, NGS‐based cfDNA methylation profiling, and blood‐based protein cancer biomarker testing are performed for patients with PNs, who are diagnosed as high‐risk patients through LDCT and subsequently undergo surgical resections, with tissue sections pathologically examined and classified. Using pathological classification as the gold standard, statistical and machine learning methods are used to select molecular markers associated with tissue's malignant classification based on a 98‐patient discovery cohort (28 benign and 70 malignant), and to construct an integrative multianalytical model for tissue malignancy prediction. Predictive models based on individual testing platforms have shown varying levels of performance, while their final integrative model produces an area under the receiver operating characteristic curve (AUC) of 0.85. The model's performance is further confirmed on a 29‐patient independent validation cohort (14 benign and 15 malignant, with power > 0.90), reproducing AUC of 0.86, which translates to an overall sensitivity of 80% and specificity of 85.7%.</p>

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

M C Liu,G R Oxnard,E A Klein,C Swanton,M V Seiden,CCGA Consortium,Minetta C Liu,Geoffrey R Oxnard,Eric A Klein,David Smith,Donald Richards,Timothy J Yeatman,Allen L Cohn,Rosanna Lapham,Jessica Clement,Alexander S Parker,Mohan K Tummala,Kristi McIntyre,Mikkael A Sekeres,Alan H Bryce,Robert Siegel,Xuezhong Wang,David P Cosgrove,Nadeem R Abu-Rustum,Jonathan Trent,David D Thiel,Carlos Becerra,Manish Agrawal,Lawrence E Garbo,Jeffrey K Giguere,Ross M Michels,Ronald P Harris,Stephen L Richey,Timothy A McCarthy,David M Waterhouse,Fergus J Couch,Sharon T Wilks,Amy K Krie,Rama Balaraman,Alvaro Restrepo,Michael W Meshad,Kimberly Rieger-Christ,Travis Sullivan,Christine M Lee,Daniel R Greenwald,William Oh,Che-Kai Tsao,Neil Fleshner,Hagen F Kennecke,Maged F Khalil,David R Spigel,Atisha P Manhas,Brian K Ulrich,Philip A Kovoor,Christopher Stokoe,Jay G Courtright,Habte A Yimer,Timothy G Larson,Charles Swanton,Michael V Seiden,Steven R Cummings,Farnaz Absalan,Gregory Alexander,Brian Allen,Hamed Amini,Alexander M Aravanis,Siddhartha Bagaria,Leila Bazargan,John F Beausang,Jennifer Berman,Craig Betts,Alexander Blocker,Joerg Bredno,Robert Calef,Gordon Cann,Jeremy Carter,Christopher Chang,Hemanshi Chawla,Xiaoji Chen,Tom C Chien,Daniel Civello,Konstantin Davydov,Vasiliki Demas,Mohini Desai,Zhao Dong,Saniya Fayzullina,Alexander P Fields,Darya Filippova,Peter Freese,Eric T Fung,Sante Gnerre,Samuel Gross,Meredith Halks-Miller,Megan P Hall,Anne-Renee Hartman,Chenlu Hou,Earl Hubbell,Nathan Hunkapiller,Karthik Jagadeesh,Arash Jamshidi,Roger Jiang,Byoungsok Jung,TaeHyung Kim,Richard D Klausner,Kathryn N Kurtzman,Mark Lee,Wendy Lin,Jafi Lipson,Hai Liu,Qinwen Liu,Margarita Lopatin,Tara Maddala,M Cyrus Maher,Collin Melton,Andrea Mich,Shivani Nautiyal,Jonathan Newman,Joshua Newman,Virgil Nicula,Cosmos Nicolaou,Ongjen Nikolic,Wenying Pan,Shilpen Patel,Sarah A Prins,Richard Rava,Neda Ronaghi,Onur Sakarya,Ravi Vijaya Satya,Jan Schellenberger,Eric Scott,Amy J Sehnert,Rita Shaknovich,Avinash Shanmugam,K C Shashidhar,Ling Shen,Archana Shenoy,Seyedmehdi Shojaee,Pranav Singh,Kristan K Steffen,Susan Tang,Jonathan M Toung,Anton Valouev,Oliver Venn,Richard T Williams,Tony Wu,Hui H Xu,Christopher Yakym,Xiao Yang,Jessica Yecies,Alexander S Yip,Jack Youngren,Jeanne Yue,Jingyang Zhang,Lily Zhang,Lori Quan Zhang,Nan Zhang,Christina Curtis,Donald A Berry

DOI: https://doi.org/10.1016/j.annonc.2020.02.011

Abstract:Background: Early cancer detection could identify tumors at a time when outcomes are superior and treatment is less morbid. This prospective case-control sub-study (from NCT02889978 and NCT03085888) assessed the performance of targeted methylation analysis of circulating cell-free DNA (cfDNA) to detect and localize multiple cancer types across all stages at high specificity. Participants and methods: The 6689 participants [2482 cancer (>50 cancer types), 4207 non-cancer] were divided into training and validation sets. Plasma cfDNA underwent bisulfite sequencing targeting a panel of >100 000 informative methylation regions. A classifier was developed and validated for cancer detection and tissue of origin (TOO) localization. Results: Performance was consistent in training and validation sets. In validation, specificity was 99.3% [95% confidence interval (CI): 98.3% to 99.8%; 0.7% false-positive rate (FPR)]. Stage I-III sensitivity was 67.3% (CI: 60.7% to 73.3%) in a pre-specified set of 12 cancer types (anus, bladder, colon/rectum, esophagus, head and neck, liver/bile-duct, lung, lymphoma, ovary, pancreas, plasma cell neoplasm, stomach), which account for ∼63% of US cancer deaths annually, and was 43.9% (CI: 39.4% to 48.5%) in all cancer types. Detection increased with increasing stage: in the pre-specified cancer types sensitivity was 39% (CI: 27% to 52%) in stage I, 69% (CI: 56% to 80%) in stage II, 83% (CI: 75% to 90%) in stage III, and 92% (CI: 86% to 96%) in stage IV. In all cancer types sensitivity was 18% (CI: 13% to 25%) in stage I, 43% (CI: 35% to 51%) in stage II, 81% (CI: 73% to 87%) in stage III, and 93% (CI: 87% to 96%) in stage IV. TOO was predicted in 96% of samples with cancer-like signal; of those, the TOO localization was accurate in 93%. Conclusions: cfDNA sequencing leveraging informative methylation patterns detected more than 50 cancer types across stages. Considering the potential value of early detection in deadly malignancies, further evaluation of this test is justified in prospective population-level studies.
Multi-omics integrated circulating cell-free DNA genomic signatures enhanced the diagnostic performance of early-stage lung cancer and postoperative minimal residual disease

Yun Li,Guanchao Jiang,Wendy Wu,Hao Yang,Yichen Jin,Manqi Wu,Wenjie Liu,Airong Yang,Olga Chervova,Sujie Zhang,Lu Zheng,Xueying Zhang,Fengxia Du,Nnennaya Kanu,Lin Wu,Fan Yang,Jun Wang,Kezhong Chen

DOI: https://doi.org/10.1016/j.ebiom.2023.104553

IF: 11.205

2023-05-01

EBioMedicine

Abstract:BACKGROUND: Liquid biopsy is a promising non-invasive alternative for cancer screening and minimal residual disease (MRD) detection, although there are some concerns regarding its clinical applications. We aimed to develop an accurate detection platform based on liquid biopsy for both cancer screening and MRD detection in patients with lung cancer (LC), which is also applicable to clinical use.METHODS: We applied a modified whole-genome sequencing (WGS) -based High-performance Infrastructure For MultIomics (HIFI) method for LC screening and postoperative MRD detection by combining the hyper-co-methylated read approach and the circulating single-molecule amplification and resequencing technology (cSMART2.0).FINDINGS: For early screening of LC, the LC score model was constructed using the support vector machine, which showed sensitivity (51.8%) at high specificity (96.3%) and achieved an AUC of 0.912 in the validation set prospectively enrolled from multiple centers. The screening model achieved detection efficiency with an AUC of 0.906 in patients with lung adenocarcinoma and outperformed other clinical models in solid nodule cohort. When applied the HIFI model to real social population, a negative predictive value (NPV) of 99.92% was achieved in Chinese population. Additionally, the MRD detection rate improved significantly by combining results from WGS and cSMART2.0, with sensitivity of 73.7% at specificity of 97.3%.INTERPRETATION: In conclusion, the HIFI method is promising for diagnosis and postoperative monitoring of LC.FUNDING: This study was supported by CAMS Innovation Fund for Medical Sciences, Chinese Academy of Medical Sciences, National Natural Science Foundation of China, Beijing Natural Science Foundation and Peking University People's Hospital.

medicine, research & experimental
Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection

Hua Bao,Zheng Wang,Xiaoji Ma,Wei Guo,Xiangyu Zhang,Wanxiangfu Tang,Xin Chen,Xinyu Wang,Yikuan Chen,Shaobo Mo,Naixin Liang,Qianli Ma,Shuyu Wu,Xiuxiu Xu,Shuang Chang,Yulin Wei,Xian Zhang,Hairong Bao,Rui Liu,Shanshan Yang,Ya Jiang,Xue Wu,Yaqi Li,Long Zhang,Fengwei Tan,Qi Xue,Fangqi Liu,Sanjun Cai,Shugeng Gao,Junjie Peng,Jian Zhou,Yang Shao

DOI: https://doi.org/10.1186/s12943-022-01594-w

IF: 37.3

2022-06-12

Molecular Cancer

Abstract:Early detection can benefit cancer patients with more effective treatments and better prognosis, but existing early screening tests are limited, especially for multi-cancer detection. This study investigated the most prevalent and lethal cancer types, including primary liver cancer (PLC), colorectal adenocarcinoma (CRC), and lung adenocarcinoma (LUAD). Leveraging the emerging cell-free DNA (cfDNA) fragmentomics, we developed a robust machine learning model for multi-cancer early detection. 1,214 participants, including 381 PLC, 298 CRC, 292 LUAD patients, and 243 healthy volunteers, were enrolled. The majority of patients ( N = 971) were at early stages (stage 0, N = 34; stage I, N = 799). The participants were randomly divided into a training cohort and a test cohort in a 1:1 ratio while maintaining the ratio for the major histology subtypes. An ensemble stacked machine learning approach was developed using multiple plasma cfDNA fragmentomic features. The model was trained solely in the training cohort and then evaluated in the test cohort. Our model showed an Area Under the Curve (AUC) of 0.983 for differentiating cancer patients from healthy individuals. At 95.0% specificity, the sensitivity of detecting all cancer reached 95.5%, while 100%, 94.6%, and 90.4% for PLC, CRC, and LUAD, individually. The cancer origin model demonstrated an overall 93.1% accuracy for predicting cancer origin in the test cohort (97.4%, 94.3%, and 85.6% for PLC, CRC, and LUAD, respectively). Our model sensitivity is consistently high for early-stage and small-size tumors. Furthermore, its detection and origin classification power remained superior when reducing sequencing depth to 1× (cancer detection: ≥ 91.5% sensitivity at 95.0% specificity; cancer origin: ≥ 91.6% accuracy). In conclusion, we have incorporated plasma cfDNA fragmentomics into the ensemble stacked model and established an ultrasensitive assay for multi-cancer early detection, shedding light on developing cancer early screening in clinical practice.

oncology,biochemistry & molecular biology
Nanomaterials Augmented LDI-TOF-MS for Pancreatic Ductal Adenocarcinoma Diagnosis and Classification.

Yaolin Xu,Dansong Wang,Tiantao Kuang,Wenchuan Wu,Xuefeng Xu,Dayong Jin,Hua Zhang,Sheng Zhong,Yunbing Wang,Wenhui Lou

DOI: https://doi.org/10.1200/jco.2020.38.15_suppl.e16761

IF: 45.3

2020-01-01

Journal of Clinical Oncology

Abstract:e16761 Background: Pancreatic ductal adenocarcinoma (PAAD) is one type of cancer with poor prognosis. Although CA 19-9 was the most common serological marker for cancer screening and surveillance after treatment, there are still unignorable limitations, including low sensitivity, possible false-negatives/positives owing to confounding conditions. Reliable non-invasive diagnostics is in urgent need. As PAAD is increasingly considered as a metabolic disorder, serum metabolite profiling is becoming critical to reveal important cancer-related bioinformation. This work proposes a novel LDI-TOF-MS technique for PAAD screening and diagnosis. Methods: An LDI-TOF-MS platform was established for cancer screening. All mass spectrum was collected within a mass range of 100 to 1,100 Da, while the spectra were manually examined using the FlexAnalysis 3.4 software (Bruker Daltonics, Bremen, Germany). In a typical process, 0.5 uL of serum samples were spotted on a polished steel target plate MTP 384 and air-dried followed by another 1 uL of GNS or SiNW nanomaterials. The spectra were then acquired in the reflection positive mode with smartbeam-II laser at 355 nm with laser frequency of 1,000 Hz. A random walk of 25 shots at raster spot and 20 different spots were measured for each individual sample, therefore, 500 satisfactory shots were obtained. Results: By taking advantage of 3D nanostructures and machine learning, we applied proposed approach to 94 patients with PAAD, as well as 203 healthy controls (Table). The results demonstrated an average sensitivity of 99% and a specificity over 98% in detecting cancers. 11 of 94 PAAD patients (11.70%) were CA 19-9 negative (CA19-9 < 37U/ml, stage I n = 2, stage II n = 7, stage III n = 1 and stage IV n = 1). LDI-TOF-MS recognized almost all CA 19-9-negative PAAD. The sensitivity and specificity were obviously superior to CA 19-9 in PAAD: only 1 of 94 PAAD (1.06%) were misclassified as healthy controls. In contrast, CA19-9 positive and CA 19-9 negative PAADs were not readily distinguished by this method. Therefore, this method was independent of tumor markers. Conclusions: Result suggested strong potential of proposed technique as a low-cost, superior precision, and high-throughput procedure for PAAD diagnosis and beyond. [Table: see text]
Profiling Breast Tumor Heterogeneity and Identifying Breast Cancer Subtypes Through Tumor‐Associated Immune Cell Signatures and Immuno Nano Sensors

Deeptha Ishwar,Srilakshmi Premachandran,Sunit Das,Krishnan Venkatakrishnan,Bo Tan

DOI: https://doi.org/10.1002/smll.202406475

IF: 13.3

2024-10-26

Small

Abstract:This study utilizes an ultrafast laser‐fabricated Immuno Nano Sensor to uncover metabolic heterogeneity in breast tumors using immune cells. By combining spectral markers from NK and T cells with machine learning, high accuracy is achieved in distinguishing cancer from healthy samples, identifying primary versus metastatic tumors, and determining Estrogen Receptor (ER)/Progesterone Receptor (PR)B status at the single‐cell level. This approach promises a transformative impact on breast cancer diagnosis and management through minimally invasive liquid biopsy. Breast cancer is a complex and heterogeneous disease with varying cellular, genetic, epigenetic, and molecular expressions. The detection of intratumor heterogeneity in breast cancer poses significant challenges due to its complex multifaceted characteristics, yet its identification is crucial for guiding effective treatment decisions and understanding the disease progression. Currently, there exists no method capable of capturing the full extent of breast tumor heterogeneity. In this study, the aim is to identify and characterize metabolic heterogeneity in breast tumors using immune cells and an ultrafast laser‐fabricated Immuno Nano Sensor. Combining spectral markers from both Natural Killer (NK) and T cells, a machine‐learning approach is implemented to distinguish cancer from healthy samples, identify primary versus metastatic tumors, and determine estrogen receptor (ER)/progesterone receptor (PR) status at the single‐cell level. The platform successfully distinguished heterogeneous breast cancer samples from healthy individuals, achieving 97.8% sensitivity and 92.2% specificity, and accurately identified primary tumors from metastatic tumors. Characteristic spectral signatures allow for discrimination between ER/PR‐positive and negative tumors with 97.5% sensitivity. This study demonstrates the potential of immune cell‐based metabolic profiling in providing a comprehensive assessment of breast tumor heterogeneity and paving the way for minimally invasive liquid biopsy approaches in breast cancer diagnosis and management.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
Single Nanoparticle Counting-Based Liquid Biopsy for Cancer Diagnosis

Min Jiang,Jing Zhou,Xiaobo Xie,Zili Huang,Rui Liu,Yi Lv

DOI: https://doi.org/10.1021/acs.analchem.2c03367

IF: 7.4

2022-10-27

Analytical Chemistry

Abstract:Liquid biopsy has become a sought-after technique for disease diagnosis because it provides real-time, dynamic, and comprehensive information that can alleviate the dilemmas faced by tissue biopsy. Multiplexed microRNAs (miRNAs) have been demonstrated to be promising biomarkers in liquid biopsy but fall short in providing simple and sensitive analytical methods. In this work, we established a novel nanoparticle counting strategy to accomplish simultaneous analysis of three breast...

chemistry, analytical
Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization

Fenglong Bie,Zhijie Wang,Yulong Li,Wei Guo,Yuanyuan Hong,Tiancheng Han,Fang Lv,Shunli Yang,Suxing Li,Xi Li,Peiyao Nie,Shun Xu,Ruochuan Zang,Moyan Zhang,Peng Song,Feiyue Feng,Jianchun Duan,Guangyu Bai,Yuan Li,Qilin Huai,Bolun Zhou,Yu S. Huang,Weizhi Chen,Fengwei Tan,Shugeng Gao

DOI: https://doi.org/10.1038/s41467-023-41774-w

IF: 16.6

2023-09-27

Nature Communications

Abstract:Abstract Multimodal epigenetic characterization of cell-free DNA (cfDNA) could improve the performance of blood-based early cancer detection. However, integrative profiling of cfDNA methylome and fragmentome has been technologically challenging. Here, we adapt an enzyme-mediated methylation sequencing method for comprehensive analysis of genome-wide cfDNA methylation, fragmentation, and copy number alteration (CNA) characteristics for enhanced cancer detection. We apply this method to plasma samples of 497 healthy controls and 780 patients of seven cancer types and develop an ensemble classifier by incorporating methylation, fragmentation, and CNA features. In the test cohort, our approach achieves an area under the curve value of 0.966 for overall cancer detection. Detection sensitivity for early-stage patients achieves 73% at 99% specificity. Finally, we demonstrate the feasibility to accurately localize the origin of cancer signals with combined methylation and fragmentation profiling of tissue-specific accessible chromatin regions. Overall, this proof-of-concept study provides a technical platform to utilize multimodal cfDNA features for improved cancer detection.

multidisciplinary sciences
All-in-one nanoflare biosensor combined with catalyzed hairpin assembly amplification for in situ and sensitive exosomal miRNA detection and cancer classification

Xue-Wei Zhang,Li Du,Meng-Xian Liu,Jian-Hua Wang,Shuai Chen,Yong-Liang Yu

DOI: https://doi.org/10.1016/j.talanta.2023.125145

IF: 6.1

2023-09-04

Talanta

Abstract:Exosomal miRNAs can reflect tumor progression and metastasis, and are effective biomarkers for cancer diagnosis. However, the accuracy of exosomal miRNA-based cancer diagnosis is limited by the low sensitivity and complicated RNA extraction of traditional approaches. Herein, a novel biosensor is developed for in situ, extraction-free, and highly sensitive analysis of exosomal miRNAs via nanoflare combined with catalyzed hairpin assembly (CHA) amplification. Without cumbersome and costly miRNA extraction or transfection agents, nanoflare can directly enter the exosomes to bind target miRNAs and generate a fluorescence signal that can be amplified by the CHA reaction to achieve the in situ and highly sensitive detection of exosomal miRNAs. Under the optimal conditions, the detection limit of 5 aM is obtained for three exosomal miRNAs, which is an order of magnitude lower than quantitative real time polymerase chain reaction (qRT-PCR). In combination with the linear discriminant analysis algorithm, five exosomes are distinguished with 100% accuracy. Importantly, five cancers including breast, lung, liver, cervical, and colon cancer from 64 patients are distinguished with 99% accuracy by testing exosomal miRNAs in clinical plasma. This simple, accurate, and sensitive biosensor holds the potential to be expanded into clinical non-invasive cancer diagnostic tests.

chemistry, analytical
Nanoconfined liquid phase nanoextraction combined with in-fiber derivatization for simultaneous quantification of seventy amino-containing metabolites in plasma by LC-MS/MS: Exploration of lung cancer screening model

Chunyu Yu,Qian Zhang,Liyuan Wang,Yiwen Zhang,Meiyu Cui,Kaishun Bi,Donghao Li,Qing Li

DOI: https://doi.org/10.1016/j.talanta.2022.123452

IF: 6.1

2022-08-01

Talanta

Abstract:Targeted metabolomics with absolute quantification is widely applied in biomarker identification and drug screening. However, due to the complexity of biological matrix and trace amount of metabolites in plasma, simultaneous quantification of highly polar metabolites in plasma with broad coverage in short time is still challenging. Herein, we proposed a nanoconfined liquid phase nanoextraction (NLPNE) combined with in-fiber derivatization (IFD) strategy that enabled simultaneous quantification of seventy amino-containing analytes in plasma, including amines, nucleosides and their metabolites. Methanol−water (2:1, v/v) was selected as nanoconfined solvent (NCS) to quickly extract highly polar analytes based on the nanoconfinement effect, followed by IFD process directly performed by adding the derivatization reagent benzoyl chloride (BzCl) within 5 min. Besides saving time, this combination strategy was environment-friendly with little organic solvent consumption and cost-effective by using reusable carbon nanofibers. Furthermore, the sensitivity was increased up to 4.92-fold compared with protein precipitation (PP) based conventional derivatization method. Key factors that affected derivatization efficiency including the derivatization time, the amount of derivatization reagent, desorption solution and CNFs, were optimized by response surface methodology (RSM). After systematical method validation, this methodology was applied to determine the multi-metabolites index in plasma of lung cancer using an integrated data processing workflow. Then lung cancer diagnosis model was established through binary logistic regression analysis to make a reference for quick lung cancer screening clinically. Taken together, the NLPNE-IFD LC-MS/MS method for targeted metabolomics enables simultaneous quantification of seventy amino-containing analytes with advantages of broad coverage, high sensitivity, time- and solvent-saving, which could be used on cancer diagnosis clinically.

chemistry, analytical
Kidney transplantation in Alport's syndrome.

Francesco Scolari,B. Valzorio,F. Fasciolo,O. Carli,V. Vizzardi,P. Gaggia,P. Tira,R. Maffeis,Stefano Bonardelli,Rosario Maiorca

DOI: https://doi.org/10.1159/000059892

1997-10-22

Contributions to Nephrology

Abstract:
Biofluid Metabolic Profiling for Lung Cancer Screening via Reactive Matrix-Assisted Laser Desorption Ionization Mass Spectrometry

Zhengzhou Li,Chen Sun,Ke Jia,Xiao Wang,Jing Han,Junyu Chen,Jiyun Wang,Huihui Liu,Zongxiu Nie

DOI: https://doi.org/10.1021/acs.analchem.3c02015

2023-08-15

Abstract:Lung cancer (LC) has the highest mortality rate among various cancer diseases. Developing an early screening method for LC with high classification accuracy is essential. Herein, 2-hydrazinoquinoline (2-HQ) is utilized as a dual-mode reactive matrix for metabolic fingerprint analysis and LC screening via matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS). Metabolites in both positive mode and negative mode can be detected using 2-HQ as the matrix, and derivative analysis of aldehyde and ketone compounds can be achieved simultaneously. Hundreds of serum and urine samples from LC patients and healthy volunteers were analyzed. Combined with machine learning, LC patients and healthy volunteers were successfully distinguished with a high area under the curve value (0.996 for blind serum samples and 0.938 for urine). The MS signal was identified for metabolic profiling, and dysregulated metabolites of the LC group were analyzed. The above results showed that this method has great potential for rapid screening of LC.
Highly sensitive microfluidic sensor using integrated optical fiber and real-time single-cell Raman spectroscopy for diagnosis of pancreatic cancer

Renhao Ni,Kaixin Ge,Yang Luo,Tong Zhu,Zeming Hu,Min Li,Pan Tao,Jinyi Chi,Guanron Li,Haojun Yuan,Qian Pang,Wanlei Gao,Peiqing Zhang,Yabin Zhu

DOI: https://doi.org/10.1016/j.bios.2024.116616

2024-08-03

Abstract:Pancreatic cancer is notoriously lethal due to its late diagnosis and poor patient response to treatments, posing a significant clinical challenge. This study introduced a novel approach that combines a single-cell capturing platform, tumor-targeted silver (Ag) nanoprobes, and precisely docking tapered fiber integrated with Raman spectroscopy. This approach focuses on early detection and progression monitoring of pancreatic cancer. Utilizing tumor-targeted Ag nanoparticles and tapered multimode fibers enhances Raman signals, minimizes light loss, and reduces background noise. This advanced Raman system allows for detailed molecular spectroscopic examination of individual cells, offering more practical information and enabling earlier detection and accurate staging of pancreatic cancer compared to conventional multicellular Raman spectroscopy. Transcriptomic analysis using high-throughput gene screening and transcriptomic databases confirmed the ability and accuracy of this method to identify molecular changes in normal, early, and metastatic pancreatic cancer cells. Key findings revealed that cell adhesion, migration, and the extracellular matrix are closely related to single-cell Raman spectroscopy (SCRS) results, highlighting components such as collagen, phospholipids, and carotene. Therefore, the SCRS approach provides a comprehensive view of the molecular composition, biological function, and material changes in cells, offering a novel, accurate, reliable, rapid, and efficient method for diagnosing and monitoring pancreatic cancer.
Early Cancer Detection Using Multi-Omic Approach Including Epigenetic Signal from Ultra-Small Fragments.

Johnny Wu,Xin-Xing Li,Huabang Zhou,Wendi Liu,Fenfen Wang,Qianqian Yao,Dongsheng Lu,Huiqi Lu,Hongyan Wang,Tobias Wittkop,Paul Tang,Heping Hu,Xiaodong Cheng,Zhiqian Hu,Malek Faham,Li Weng

DOI: https://doi.org/10.1200/jco.2020.38.15_suppl.e13561

IF: 45.3

2020-01-01

Journal of Clinical Oncology

Abstract:e13561 Background: Genetic and epigenetic signals from plasma cell-free DNA (cfDNA) as well as proteins have been shown to detect cancer early. We have previously developed Circular Ligation and Amplification (CLAmp-seq) to detect mutations very sensitively and demonstrated higher performance than molecular barcode-based methods. The same single strand based technology yielded a much larger proportion of small fragments ( < 100 bp) than traditional methods typically relying on double stranded ligation, allowing us to investigate epigenetic signature of cancer in ultra-short fragments. We sought to measure the performance using a multi-omics approach of these genetic and epigenetic changes as well as proteins in detecting colorectal cancer (CRC), ovarian cancer (OC) and hepatocellular carcinoma (HCC). Methods: A healthy and a late stage cancer sample were assessed by whole genome sequencing (WGS) using CLAmp-seq. Then we analyzed cfDNA from plasma samples of 731 patients, including 69 CRC, 57 HCC, 49 OC patients and 556 age-matched healthy individuals. Out of the diseased samples, the numbers for stages I-IV are 49, 39, 71, and 16, respectively. CLAmp-seq WGS was performed on 58 healthy and 66 cancer samples to discover cancer epigenetic signature. In addition, all the samples were analyzed for a panel of proteins and a CLAmp-seq targeted panel that includes known mutation sites. Results: Using CLAmp-Seq in late stage cancer showed 33% of its fragments as smaller than 100 bp compared to 15% in healthy and < 1% in late stage by double stranded library prep. In addition, the difference in fragment size between late stage cancer and healthy was 29bp using CLAmp-Seq and 12bp using traditional double stranded prep. This focused our attention to detect epigenetic signature specific to cancer on the small fragments using CLAmp-Seq. Using data from whole genome analysis we demonstrated a performance using the epigenetic signature alone of 50% sensitivity at 97% specificity. Combined with mutations and proteins, we obtained at specificity of 97% sensitivities of 50%, 88%, 88%, and 100% in stage I, II, III, and IV, respectively. At the same 97% specificity we obtained the sensitivities of 73%, 100%, and 85% in CRC, OC, and HCC, respectively. Conclusions: We have demonstrated that CLAmp-Seq detects small fragments that are enriched in cancer. We have found predictive epigenetic signature in these small fragments. When combined with mutations and proteins we obtained a performance of 80% sensitivity at 97% specificity.

Metabolism and thermoregulation in the forest shrew Myosorex varius (Soricidae: Crocidurinae).

Integrative Serum Metabolic Fingerprints Based Multi‐Modal Platforms for Lung Adenocarcinoma Early Detection and Pulmonary Nodule Classification

CancerScreen: A Novel Ultrasensitive Liquid Biopsy for Early-Stage Cancer Detection by Ctdna Duplex Sequencing and Tissue of Origin Identification with Supervised Machine Learning.

Multiplexed Imaging with Coordination Nanoparticles for Cancer Diagnosis and Therapy

Noninvasive Cancer Detection by Extracting and Integrating Multi-Modal Data from Whole-Methylome Sequencing of Plasma Cell-Free DNA

Multidimensional Interactive Cascading Nanochips for Detection of Multiple Liver Diseases via Precise Metabolite Profiling

Non-invasive Lung Cancer Diagnosis and Prognosis Based on Multi-Analyte Liquid Biopsy.

A Noninvasive Multianalytical Approach for Lung Cancer Diagnosis of Patients with Pulmonary Nodules

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

Multi-omics integrated circulating cell-free DNA genomic signatures enhanced the diagnostic performance of early-stage lung cancer and postoperative minimal residual disease

Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection

Nanomaterials Augmented LDI-TOF-MS for Pancreatic Ductal Adenocarcinoma Diagnosis and Classification.

Profiling Breast Tumor Heterogeneity and Identifying Breast Cancer Subtypes Through Tumor‐Associated Immune Cell Signatures and Immuno Nano Sensors

Single Nanoparticle Counting-Based Liquid Biopsy for Cancer Diagnosis

Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization

All-in-one nanoflare biosensor combined with catalyzed hairpin assembly amplification for in situ and sensitive exosomal miRNA detection and cancer classification

Nanoconfined liquid phase nanoextraction combined with in-fiber derivatization for simultaneous quantification of seventy amino-containing metabolites in plasma by LC-MS/MS: Exploration of lung cancer screening model

Kidney transplantation in Alport's syndrome.

Biofluid Metabolic Profiling for Lung Cancer Screening via Reactive Matrix-Assisted Laser Desorption Ionization Mass Spectrometry

Highly sensitive microfluidic sensor using integrated optical fiber and real-time single-cell Raman spectroscopy for diagnosis of pancreatic cancer

Early Cancer Detection Using Multi-Omic Approach Including Epigenetic Signal from Ultra-Small Fragments.